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The number of incident cancers and long-term cancer survivors is expected to increase 
substantially for at least a decade. Advanced technology radiotherapies, e.g., using 
beams of protons and photons, offer dosimetric advantages that theoretically yield 
better outcomes. In general, evidence from controlled clinical trials and epidemiology 
studies are lacking. To conduct these studies, new research methods and infrastructure 
will be needed. In the paper, we review several key research methods of relevance to late 
effects after advanced technology proton-beam and photon-beam radiotherapies. In 
particular, we focus on the determination of exposures to therapeutic and stray radiation 
and related uncertainties, with discussion of recent advances in exposure calculation 
methods, uncertainties, in  silico studies, computing infrastructure, electronic medical 
records, and risk visualization. We identify six key areas of methodology and infrastruc-
ture that will be needed to conduct future outcome studies of radiation late effects.
Keywords: late effects, dose, risk, measurement, calculation, proton, photon
iNTRODUCTiON
About one in two men and women born today will be diagnosed with some form of cancer in 
their lifetime (1). Worldwide cancer incidence in 2012 was estimated at 14.1 million new cases 
and 8.2 million deaths (2). In the United States, cancer incidence rates are projected to generally 
stabilize over the next decade, but the incidence will increase by more than 20% due to changes in 
demographics (3). Almost two-thirds of all cancer patients receive some form of radiation therapy 
during the course of treatment (4), predominantly with external-beam photon therapy. Treatments 
with beams of charged particles have become popular, especially proton therapy (5), and a few heavier 
charged particle facilities have been built in Europe and Asia for research and patient care. The main 
rationale for using charged particle beams is that they sterilize the tumor, like X-ray therapies, while 
delivering less radiation dose to healthy tissues (6, 7).
Advances in radiation therapy have contributed to improvements in long-term outcomes 
for cancer patients. For example, 5-year survival of cancer in the United States has increased to 
approximately 68% in adults and 83% in children (8). By 2020, there will be almost 20 million cancer 
survivors in the United States (9). Long-term survivors are at increased risk to develop treatment-
induced side effects, such as radiogenic second cancer, complications of the cardiovascular (10, 11) 
and central nervous (12, 13) systems, fertility problems (14), and myriad other toxicities (15). These 
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problems can be caused by disease (e.g., damage caused by a pri-
mary cancer) or by medical care, such as surgery, chemotherapy, 
and radiation therapy. For many patients, these will play out long 
after the primary cancer is cured. For example, in survivors of 
childhood cancer, the risks of morbidity and mortality remain 
elevated beyond the fourth decade of life (16).
The link between radiation therapy and several serious late 
effects has been well documented in the literature. Radiation epi-
demiology studies revealed increased risk for subsequent cancers 
after radiotherapy (17). One of the most striking examples being 
the cumulative risk of subsequent breast cancer after radiotherapy 
for Hodgkin’s lymphoma of 30% by age 55 (18). The clinical 
oncology literature reports that radiation is implicated in many 
subsequent cancers (19) and that mortality of primary cancers is 
decreasing, with increases in rates of mortality attributable to sub-
sequent neoplasms, cardiac death, and pulmonary death largely 
due to treatment-related causes (20). Although radiotherapy 
significantly reduces breast cancer mortality and recurrence, the 
heart dose from older radiation treatments was found to materially 
impact total long-term survival (21). For some types of cancers, 
and in some pediatric cancers, second cancers can cause more 
deaths than the primary cancers (22). Second cancers account 
for 17–19% of all cancers, and, as a group, are one of the most 
common cancers in the USA (23). In adults, the proportion of 
second cancers related to radiotherapy was estimated at approxi-
mately 8% on average, with proportions varying from 4 to 24% 
for the specific sites considered (24). Corresponding estimates for 
children are not currently known but are likely to be consider-
ably higher, given the increased radiosensitivity of children to 
some cancers and generally longer survival. For these and other 
reasons, the assessment of risks of late effects after radiotherapy 
has received increasing attention in the literature, including the 
impact of advanced technologies on outcomes (25, 26).
Advances in technology seek to improve cancer outcomes 
in two major ways, namely, by irradiating cancerous tissues in 
ways that lead to improved control of tumors and by reducing 
doses to healthy tissues to reduce treatment complications. Many 
advanced technologies have been implemented to further these 
goals, including treatment systems that use modulated beams 
of photons and protons. Unlike most new medical devices and 
drugs, advanced RTs are being widely deployed based on predicted 
improvements in outcome rather than superiority observed in 
prospective randomized clinical trials. The necessity of such 
trials is controversial (27). Furthermore, large economic forces 
are at play; proton and heavy-ion treatment units are the most 
expensive medical devices on the market and are perceived as a 
potentially disruptive technology in oncology. Clearly, additional 
new scientific approaches and knowledge would help to inform 
decision making in the future (28).
Currently, major gaps in scientific knowledge include (1) 
the long-term health problems of long-term cancer survivors, 
especially a decade or more after exposure; (2) the impact of 
radiation modality, dose, quality, and fractionation on the risk 
of late effects; (3) the applicability of risk models derived from 
healthy populations exposed to lower dose radiation to high-dose 
fractionated exposures in populations of cancer survivors; (4) 
the applicability of population-based risk models to individual 
patients, whose sensitivity to radiogenic late effects may vary with 
genetic profile and other factors; and (5) the impact of late effects 
after advanced technology radiotherapies, including incidence, 
severity, and economic considerations. Filling these gaps will 
require new research strategies, methods, and infrastructure.
The objective of this manuscript is to provide a review of selected 
research methodologies for radiogenic late effects after advanced 
technology radiation therapies. More specifically, we review aspects 
of relevance to proton-beam and photon-beam radiotherapies. We 
focus on craniospinal irradiation (CSI) as an illustrative example 
treatment to highlight current research capabilities and their 
limitations as this is one of the treatments for which proton therapy 
could be very beneficial. In particular, we review the determina-
tion of exposures to therapeutic and stray radiation and related 
uncertainties in the context of radiation late effects.
ReCeNT ADvANCeS iN ReSeARCH 
MeTHODS
A few introductory remarks are necessary to provide a context for 
the thrust of our review. In the last decade, considerable progress 
has been made toward research methods of relevance to the risk 
of late effects after advanced technology radiation therapies. 
However, long-term clinical and epidemiological outcome stud-
ies of charged particle therapies are scarce (29). These studies are 
difficult to perform for many reasons, including a lack of dose and 
risk assessment tools that are suitable for prospective outcome 
studies. Currently, most photon therapy outcome studies are 
performed retrospectively, with the doses being reconstructed by 
specialists using proprietary research tools (30). Similar tools for 
charged particle are nascent.
To review progress and explore limitations of current tools, we 
shall consider the illustrative case of CSI for medulloblastoma. 
This is a particularly interesting case because it is common among 
pediatric brain tumors; approximately 80% of patients survive 
5 years or more (31); the therapeutic radiation fields are large, 
variable in size, shape, and anatomic location (32); the therapeu-
tic and stray radiation impacts many healthy tissues and organs 
(33); patients vary in age at diagnosis (34) and anatomic stature; 
it is commonly delivered with photon or proton beams; there are 
large differences in predicted doses and risks between photon 
and proton beams (35); genomics strongly influence outcomes 
(36); dose and risk assessments are technically challenging (26); 
and there is sufficient recent literature to form a coherent picture. 
The methodological literature includes dose measurements; dose 
calculations using clinical treatment planning systems (TPSs), 
Monte Carlo simulations, and analytical models; radiation quality; 
risk models; and other aspects.
Craniospinal irradiation attempts to limit the administration 
of tumor-sterilizing doses to several target volumes, including the 
spinal axis, the cranium, and a surgical resection volume near the 
posterior fossa. However, even the most advanced radiotherapies 
deliver low levels of stray radiation to the patient’s whole body. 
Observational data for various treatment sites revealed that nearly 
nine of every 10 subsequent tumors develop outside PTV (37). Thus, 
to fully understand late effects after external beam radiotherapy, 
FiGURe 1 | Schematic diagram of a proton therapy treatment of the 
spinal axis. The therapeutic dose is shown in red and unwanted stray 
radiation is shown in blue. The stray radiation comprises leakage radiation 
emanating from the treatment machine, and scatter radiation that is produced 
as the therapeutic radiation interacts with the patient. Figure from Ref. (26).
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one must, at a minimum, determine exposures from therapeutic 
and stray radiation to all of the organs and tissues of the body.
Assessment of Radiation exposure
Today, there are four major methods to determine radiation 
exposure from external beam radiotherapy, including measure-
ments, analytical calculations (dose algorithms embedded in 
TPSs and nascent stand-alone algorithms), and Monte Carlo 
simulations.
Traditionally, measurements are used to develop, configure, 
and test dose calculation methods of various kinds, including 
pencil beam algorithms in clinical TPSs, research Monte Carlo 
codes, and other dose models. Methodologies for the measure-
ment of therapeutic doses are generally well established and 
straightforward. Measurements of stray radiation are challenging 
and less well established. In particular, stray neutron radiation 
is experimentally difficult and subject to large uncertainties. 
High-energy photon beams produce neutrons via photoneutron 
interactions, and high-energy protons liberate neutrons via 
nuclear reactions.
Analytical dose algorithms are typically used in TPSs. They 
generally provide excellent dosimetric accuracy inside the thera-
peutic field and fast computation speeds. However, they severely 
underestimate stray radiation exposures, especially leakage 
radiation emanating from the treatment unit (38). Consequently, 
they are not suitable for research on the effects of radiation in 
that region (Figure  1). Recently, analytical models have been 
developed to calculate both therapeutic and stray radiotherapy 
exposures (Figure 2). Analytical models for whole-body expo-
sure assessments are the least well developed of the four methods.
Monte Carlo simulations are generally well suited for research 
studies that require calculations of radiation exposures both 
inside and outside the treatment field. Of the four methods 
discussed here, the Monte Carlo method has advanced the most 
in recent years. For example, whole-body dose assessments that 
were computationally intractable in 2000 are now feasible in a 
research setting. This progress is attributable to refinements 
in general-purpose Monte Carlo codes, their adaptation to 
radiotherapy applications, and advances in parallel computing 
and low-cost electronic memory. Most Monte Carlo systems 
for radiotherapy simulations are built on general-purpose, full-
featured codes, such as MCNP/X (39) and FLUKA (40, 41) with 
additional radiotherapy pre- and post-processing codes (42, 43), 
or with toolkits, such as GEANT4 (44) with radiotherapy pack-
ages (45). Important features include good interaction data and 
models, advanced source modeling and tallying features, parallel 
computing capability, variance reduction options, and statistical 
tests for convergence. Despite stunning breakthroughs in capa-
bilities, today the Monte Carlo simulation method is seldom used 
for clinical treatment planning. One of the main reasons is that 
the method requires high-performance computing resources.
The selection of a dose assessment method involves considera-
tion of the requirements of a particular study and the performance 
characteristics of available methods. Currently, no single method 
meets all the commonly encountered requirements on speed, 
accuracy, cost, and convenience. Consequently, most research 
studies require two or more methods to determine radiation 
doses. Traditionally, late-effect studies have utilized TPS calcula-
tions of therapeutic radiation dose and analytical calculations 
of stray radiation, where both methods were validated against 
measurements. In recent years, Monte Carlo simulations have 
played an increasing role. In the remainder of this manuscript, we 
focus on aspects of these methods that are of greatest relevance to 
researching the late effects from advanced technology radiothera-
pies, i.e., photon and proton beams. In the last part of this section, 
we mention the key advances in other disciplines that have had 
an enabling effect on the research methodologies presented here.
Proton Therapy
Interest in the late effects after proton radiation therapy has 
increased dramatically since the turn of the century, perhaps in 
part because of early publications on stray neutron exposures and 
because of the late toxicities observed after neutron beam therapy 
in previous decades. The latter experience tells a cautionary tale 
of the latent dangers of any new form of radiation treatment. 
In retrospect, it is remarkable that clinical proton therapy was 
practiced more than four decades before the first publications 
on stray neutron exposures appeared. Neutrons are of particular 
concern given their higher, but very uncertain, relative biological 
effectiveness (RBE) in humans. Neutron RBE values ware derived 
primarily from experimental data because, to date, there have not 
been any epidemiological studies that have been able to compare 
the risks with those of photon irradiation directly in a sufficient 
sample size. Binns and Hough (46) reported the first measure-
ments of neutron exposures in developmental proton therapy 
beamline, which were alarmingly high. However, that beamline 
was never used for patient treatments because of the excessive 
FiGURe 2 | Absorbed dose D as a function of lateral distance x from the photon therapy beam. The calculated and measured absorbed dose values are 
normalized to the maximum therapeutic dose at the central axis Dmax(CAX). The radiation fields were produced by electron linear accelerator. Figure from Ref. (38).
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neutron exposures. In 1998, Agosteo et al. published a seminal 
paper that reported on Monte Carlo simulations of stray photon 
and neutron exposures from proton therapy beamlines (47). Yan 
et al. (48) reported the first clinically relevant measurements of 
neutron spectra and exposures. They characterized each of the 
three heavily used clinical beamlines at the Harvard Cyclotron 
Laboratory (HCL) using multiple measurement techniques. The 
results of these three studies suggested that neutron exposures 
were not negligible and that careful attention should be paid to 
characterizing and minimizing neutron exposures for clinically 
used proton beamlines.
Indeed, a few years on, Hall (49) rescaled published neutron 
exposure data from the Harvard Cyclotron Laboratory (HCL) 
with simplistic risk calculations. He opined that passively scat-
tered proton therapy may not be indicated for some patients, 
especially children, because of the second cancer risks from the 
whole-body neutron exposures. Although the key assumptions in 
his paper would be ultimately proven incorrect, the underlying 
concerns were justified. Specifically, a large international expan-
sion of proton therapy had begun without due diligence regarding 
neutron exposures and their consequences.
By the time of Hall’s paper, systematic investigations of 
neutron exposures from proton therapy were already underway. 
Beginning in 2005, a series of reports was published that studies 
the systematics of therapeutic proton and stray neutron exposures, 
such as their dependence on proton-beam energy, field size, range 
modulation width, depth in phantom, collimator thickness, and 
other treatment factors (43, 50–60). The systematics were mostly 
investigated using general-purpose Monte Carlo simulations, a 
bellwether of the increasingly important role that Monte Carlo 
holds in radiotherapy research. Subsequent confirmatory meas-
urements have been comparatively sparse but important; bench-
mark measurements confirmed the high-energy neutron physics 
models in Monte Carlo codes (61); end-to-end benchmarking 
confirmed Monte Carlo models of diverse clinically used proton 
beamlines (50, 62); and code intercomparisons further increased 
confidence in Monte Carlo simulations for clinically relevant 
beamlines, such as that in Ref. (63).
Recently, increased attention has been paid to developing 
reference data on neutron exposures (64), on methodology 
to experimentally benchmark predictive models (65), and to 
estimate mean radiation weighting factors and RBE values for 
neutrons (66–68).
By 2009, research methodologies had advanced sufficiently 
to allow for the first dose and theoretical risk assessment study, 
which was reported for CSI that included both therapeutic and 
stray neutron radiation (33). The modeling included a refined and 
more complete analysis of a case study reported in the seminal 
paper by Miralbell et al. (69), now including dose and risk from 
stray neutron exposures from passively scattered and scanned 
proton beams. The results confirmed the qualitative finding of 
Miralbell et  al., namely, that proton therapy conferred lower 
risk than photon therapy. The modeling study contradicted 
Hall’s speculation that scanned proton beams provide substan-
tially lower risk compared with scattered proton beams. It also 
increased knowledge of the mean radiation weighting factor for 
neutrons, allowing meaningful comparisons of proton and pho-
ton CSIs, in spite of the large uncertainty in the neutron RBE for 
carcinogenesis. Limitations of the study included the use of linear 
non-threshold risk models for radiation protection (70), the use 
of a stylized adult phantom, and simplified treatment planning. 
In rapid succession, these limitations were overcome in a series 
of papers on CSI that included newer risk models for radiogenic 
cancers (71), relaxed assumptions about linear non-threshold 
(LNT) risk behavior (72), personalized voxel phantoms (73), 
and highly realistic treatment planning methods (32). Another 
study reported ways to reduce stray radiation from passively 
scattered CSI to levels approaching those from scanned beams 
(74). Conversely, adding final collimators to scanned beams may 
sharpen the lateral penumbra, thereby reducing dose just outside 
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the target (75, 76), which increases the neutron leakage exposure. 
Findings common to these studies are that many small details 
matter and that it is difficult to know a priori which details will 
have a profound effect on risk after CSI. An example of a treat-
ment factor of importance is the superior–inferior location of the 
junction of the abutting cranial and upper spinal fields, which can 
have a profound effect on thyroid risk. Another is the selection 
of margin size on the spinal fields, which has a strong impact on 
the risk to lung and other organs. Details of the research meth-
odology also matter, such as the exclusion of the contents of the 
bladder and colon when delineating the organs and tissues at risk 
(77) and blood in the heart (35).
In the last 5 years, much progress has been made toward prac-
tical analytical models of neutron leakage exposures. A simple 
analytical model was proposed in 2010 (78) for 250 MeV beams, 
improved and extended to cover the 100–250-MeV proton-beam 
energy interval (67, 79), and validated for low-energy proton 
beams for ocular treatments (79, 80). The analytical model was 
extended to include range modulation and implemented in a 
research TPS (81).
Analytical models of exposures from neutrons generated 
inside the patient were investigated by Schneider et al. (82), who 
reported a simple parameterization for a spherical water phan-
tom. Currently, analytical algorithms are lacking for predicting 
internal neutrons.
Photon Therapy
In the early 2000s, intensity modulated photon radiation therapy 
(IMRT) was widely deployed. Hall and Wuu pointed out that the 
fluence modulation increases the monitor units by a factor of 2–3, 
thereby proportionately increasing the whole-body exposures 
from leakage radiation (83). They estimated this could lead to a 
doubling of the second cancer incidence at 10 years. Hence, the 
improved sparing of normal tissue immediately surrounding the 
tumor comes at the cost of increased exposure of the whole body 
to leakage radiation.
Generally speaking, commercial TPSs use deterministic dose 
algorithms that provide adequate accuracy in-field and near-
field. However, approximately 10  cm distance or more outside 
the treatment field, the accuracy is typically worse than 40% and 
deteriorates dramatically with increasing distance. Because of the 
high incidence of late effects that are observed outside the treat-
ment field, it will be essential to solve this problem, i.e., to achieve 
a dosimetric accuracy of 20% or better in all tissues.
Specialized Monte Carlo models were developed in 1980s for 
external beam radiotherapy research. One widely used code is 
based on the Electron Gamma Shower (EGS) code (84) with an 
add-on module (BEAM) (85) to compute photon and electron 
fluences emanating from an electron linac. Another add-on 
module named DOSExyz (86) facilitates dose computation in 
matrices of voxels, e.g., from CT image sets. Several fast Monte 
Carlo codes have been developed for radiotherapy dosimetry 
applications, including Voxel Monte Carlo (VMC) (87), dose 
planning method (DPM) (88), and MCDOSE (89). Most of the 
fast Monte Carlo calculation codes are designed for in-field or 
near-field dose calculations. General purpose codes, such as 
MCNP (39) and GEANT4 (44), include physics models for the 
production and transport of photoneutrons and have been used 
in many types of radiotherapy sources and clinical accelerators. 
At least one commercial TPS offers an electron Monte Carlo 
algorithm (90, 91). There has been effort to combine the com-
mercial TPS and calibrated fast Monte Carlo codes to provide 
organ dose calculations in both in-field and out-of-field regions 
for epidemiological studies (92). The Monte Carlo method has 
been an invaluable research tool for studying therapeutic and 
stray radiation exposures.
Analytical models have been used to predict stray radiation 
exposures for several decades for conventional radiotherapy (30). 
However, the literature on models for contemporary treatment units 
and advanced treatment techniques has been extremely limited, as 
recently reviewed in Ref. (38). An empirical model was developed 
for photon CSI (93, 94) to model out-of-field radiation exposures. 
That model parameterized measured data in an approach concep-
tually similar to that of Stovall et al. (95). Recently, a fast and simple 
physics-based analytical model was reported for a widely used 
type of medical linear accelerator (38). This approach is currently 
being further validated for use with 12 different types of linacs 
and treatment techniques, including advanced technology treat-
ments and techniques, such as IMRT, volumetric modulated arc 
therapy (VMAT), IMRT with flattening-filter-free (FFF) beams, 
tomotherapy, and robotic-arm linac therapy. The advantages of a 
physics-based approach include reduced requirements for meas-
ured data, increased predictive capabilities, broader applicability, 
fast computation time, and simplicity compared to Monte Carlo 
models. Analytical models for advanced technology radiothera-
pies are progressing rapidly but not yet sufficiently developed for 
routine use in clinical treatment planning. Major challenges lie in 
balancing the competing requirements of simplicity, dosimetric 
accuracy, and applicability. With the increasing diversity of 
advanced radiotherapies, it is not yet clear if this approach will be 
able to simultaneously meet all requirements.
Measurements have long been considered the most reliable 
source of information on stray radiation exposures and are needed 
to validate predictive models. For advanced technology photon 
radiotherapies, numerous measurements have been reported in 
air, water-box phantoms, or anthropomorphic phantoms, such as 
those in Ref. (38, 64, 96, 97). Most advanced technology photon 
therapies are administered at photon energies below the thresh-
old for photoneutron production. For this reason and for brevity, 
exposures from photoneutrons are not discussed further.
In Silico Clinical Trials
In many situations, it is difficult or impossible to carry out 
observational studies, including randomized clinical trials and 
radiation epidemiology studies. We briefly review reasons for 
this that are relevant to the advanced technology radiotherapies.
There is an inherent challenge to understanding the late effects 
from “advanced technology” treatments. Specifically, by the time 
the late effects manifest, the treatment under investigation becomes 
standard or obsolete. The latency time for solid tumors typically 
is longer than 5 years and may be several decades. This problem 
is exacerbated by the decreasing technology lifetimes because of 
accelerating technological progress. Other potentially challeng-
ing factors to conducting clinical and other observational trials 
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include requirements on equipoise, accrual of sufficient patients to 
achieve statistical power and significance, and high costs.
However, good decision making in the clinical and policy 
arenas is informed by the best available evidence. If observational 
evidence is not available, evidence can be generated using the 
alternative strategy of computer simulated or in silico trials. In silico 
trials utilize representative cohorts (including detailed volumetric 
images of patient anatomy), clinically detailed and realistic treat-
ment planning methods, physically complete dose assessments 
(therapeutic and stray radiation exposures), dose–response 
functions (risk models) from previous observational studies, and 
rigorous uncertainty analyses. Comparative in  silico studies use 
paired data (both the standard and the experimental treatments 
are simulated for each patient). In silico studies are faster and less 
expensive than traditional observational trials, although their 
ultimate role will be complimentary rather than competitive.
A lack of equipoise is perhaps the greatest barrier to conducting 
a randomized clinical trial comparing photon versus proton-beam 
CSI. By the mid 2010s, the remarkable advances in research meth-
odologies made it possible to perform in silico clinical trials that 
compared predicted risks after proton and photon CSI. The dose 
reconstructions included whole-body calculations of therapeutic 
and stray radiation, all the major tissues and organs of the bodies, 
clinical realism, and the largest cohort studied (n = 17) with com-
plete dose reconstructions. The quantities reported included organ 
doses (98), radiogenic cancer risk (35), and cardiac toxicity (35, 99).
The in  silico approach enabled systematic exploration of the 
influence of host factors on predicted risk, including age at expo-
sure, attained age (72), anatomic stature, and sex on predicted risk 
(35, 100). Studies were performed to explore the risks of various 
cancer endpoints, including incidence, mortality, excess relative 
risk, excess absolute risk, lifetime attributable risk, and ratios of 
various risk quantities as well as non-cancer endpoints, such as 
cardiac toxicity (35), fertility complications (68), and radiation-
induced necrosis (101).
Some progress has been made in understanding the uncertain-
ties in comparative risk predictions in the radiotherapy setting, 
but many important questions remain open. Uncertainties in 
risks of radiogenic cancers were reviewed in Ref. (102, 103). 
The role of sensitivity tests to assess the impact of poorly known 
uncertainties in biologic aspects of risk comparisons after CSI was 
demonstrated by Newhauser et al. (33). Specifically, they showed 
that significant results can be obtained despite the large uncertain-
ties in the RBE of neutrons for carcinogenesis. Also for CSI, Zhang 
et  al. (72) reported on the influence of the risk model selected, 
including deviations from LNT behavior due to effects, such as 
cell sterilization at therapeutic doses. Uncertainties of in  silico 
trials comparing predicted risks of late effects were investigated 
using a rigorous propagation of errors by Fontenot et al. (104) and 
subsequently extended by Rechner et al. (77), Zhang et al. (99), and 
Nguyen et al. (105). These studies all depend to some extent on the 
assumption that the extrapolation of risks from low-dose acute 
exposures to high-dose fractionated exposure is the same for all 
cancer sites. This might vary from one organ or tissue to the next 
(106), e.g., due to differences in stem cell repopulation in different 
organs. Additional progress is needed to quantify the uncertain-
ties in risk models used in comparative studies, such as possible 
organ-specific variations in the transportation of risk models from 
Japanese survivors of nuclear detonations to other populations.
Given the many uncertainties in the risk modeling, it is essen-
tial to take on the challenge of developing epidemiological and 
clinical studies to assess the late effects of proton therapy directly, 
particularly in children who are known to be more radiosensitive to 
some cancers. The first randomized trial to compare the late effects 
of proton with photon therapy for breast cancer treatment was 
recently funded by PCORI and includes 22 US proton centers with 
an aim of randomizing approximately 2000 women.1 This study, 
which was not yet recruiting patients at the time of this writing, 
will test the hypothesis that proton therapy reduces cardiovascular 
disease risks compared to photon therapy. The Pediatric Proton 
Consortium Registry is currently open to enroll children treated 
with proton radiation in the United States with the goal to char-
acterize the population receiving proton therapy, regardless of 
technology used, to evaluate its benefits over other radiation thera-
pies (107). Smaller trials are underway to compare effectiveness in 
prostate, lung, and head and neck cancer. As far as we are aware, no 
large-scale randomized trials or epidemiological studies of proton 
therapy in children are currently underway. As noted previously, 
they are the patients who are at greatest risks for radiation-related 
second cancers. The American Society for Therapeutic Radiation 
Oncology advises against using proton therapy in common cancers, 
such as prostate cancer, outside well-designed clinical trials.2 As 
the number of proton therapy centers continues to expand in the 
US, Europe, and Asia, concerted efforts should be made to directly 
study the late effects of this treatment, especially the development 
of infrastructure to assess whole-body exposures.
Related Technologies
Several related technologies have had an enabling effect of 
methodological research. First and foremost is the remarkable 
advancement in the capabilities and accuracy of general-purpose 
Monte Carlo codes, a workhorse of research on medical dosimetry. 
In fact, the field of radiation oncology owes a debt of gratitude to 
the nuclear physics community for providing general-purpose 
Monte Carlo simulation codes and outstanding support, all at 
little or no cost to the medical community. Whole-body simula-
tions, which have appeared in the literature recently (100), were 
considered computationally intractable at the turn of the century 
because of limitations of the Monte Carlo codes’ capabilities, as 
well as computational expense.
Advances in high-performance computing have had a pro-
foundly enabling effect on computational dosimetry. The most 
important developments have been the proliferation of low-
cost, high-reliability, and parallel computing methods. Several 
approaches have been used, including clusters of CPUs (108), grid 
technologies (109), and graphics processing units (110).
The second most important enabling technology is the elec-
tronic medical record, which allows a high degree of automation 
and dependability. This includes standardization of file formats, 
communications protocols, and interoperability. This has been 
helpful to researchers, for example, in performing post-processing 
1 http://www.pcori.org
2 http://www.choosingwisely.org
FiGURe 3 | Distributions of dose and risk superposed on sagittal 
images of anatomy for craniospinal irradiation. (A) shows equivalent 
dose and (B–D) show lifetime risks of second cancer incidence based on 
different dose–risk relationships [LNT: linear non-threshold model, LPLA (5): 
linear plateau model with bending point at 5 Sv, and LEXP (5): linear 
exponential model with bending point at 5 Sv]. Figure from Ref. (112).
February 2016 | Volume 6 | Article 137
Newhauser et al. Late Effects after Proton and Photon Therapies
Frontiers in Oncology | www.frontiersin.org
tasks, such as anonymization of electronic radiotherapy medical 
records (111), and will become vitally important for outcome 
studies in the future.
The visualization of radiation risk and detriment will likely 
become important in the future. In particular, it appears interest-
ing to visualize risks superposed on images of patient anatomy, 
much like radiation exposure is visualized in contemporary treat-
ment planning (Figure 3). However, for a given dose distribution, 
the distribution of risk may be radically different due to variations 
in the radiation sensitivity of individual organs and tissues (26). 
From a technical standpoint, meaningful visualization of risk 
presents many challenges, some of which may be overcome (26, 
112). Risk visualization methods are nascent and are currently 
unavailable in contemporary TPSs.
Given the progress in capabilities to predict radiation expo-
sures and risks, it has become technically possible to develop 
methods to algorithmically minimize predicted risk (113). Such 
methods could become an automatic step in routine radiotherapy 
treatment planning. Algorithmic minimization of risk of late 
effects is nascent and is currently unavailable in TPSs. Substantial 
additional research, development, and validation will be required 
before this can be used for human use, e.g., in prospective clinical 
decision making regarding the care individual patients receive.
DiSCUSSiON
Worldwide, the number of incident cancer cases is expected to 
increase over the next decade. Cancer survival rates are expected 
to increase further with improved diagnosis, treatment, and 
survivorship care. For these and other reasons, additional atten-
tion must be paid to reduce the incidence of treatment-related 
morbidity, such as fatal radiogenic second cancers.
Achieving this goal will require new research strategies and 
methods to supplement and enhance the traditional ones. In 
general, each new generation of advanced technology enables the 
delivery of superior (and more complex) therapeutic and stray dose 
distributions in the body. The exposures vary with a wide variety 
of treatment factors and host factors. To prospectively assess the 
full potential of advanced technology treatments to improve out-
comes, new methods and capabilities are urgently needed to assess 
radiation exposures. Promising recent studies, including several 
examples mentioned in this review article, suggest that it might 
become feasible to routinely predict radiation exposures to all the 
tissues and organs of the body in the near future.
At the present time, clinical TPSs provide acceptable dosi-
metric accuracy for exposures to therapeutic radiation. However, 
outside the treatment field, the accuracy is generally poor and 
at distant locations, the exposures are typically not calculated 
at all. Additional research and development will be needed to 
develop dose prediction algorithms that provide an acceptable 
compromise of dosimetric accuracy, computational speed, and 
ease of use.
To accomplish that, we will need to know much more about the 
processes governing radiation exposures and risks. In recent years, 
our understanding of the magnitude and systematics of stray radia-
tion exposures has increased dramatically for advanced proton and 
photon therapies and further progress is anticipated. However, 
many key uncertainties remain regarding the magnitude of risks 
from high-dose fractionated exposures, critical substructures of 
organs (such as the heart), applicability of risk models based on 
data from the Japanese atomic bomb survivors to non-Japanese 
populations, and the RBE of neutrons. From the literature, a 
coherent picture is emerging in which stray exposures are generally 
numerically small but the corresponding risks may be large, e.g., 
30% or larger lifetime risk of second cancer for some patients. Risks 
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of radiation late effects are of particular concern for patients of 
young age and with good prognoses for long-term survival.
Advances in research methodologies and capabilities will 
be necessary. Some key needs for research and clinical settings 
include
 (1) Algorithms to calculate exposures to tissues outside the treat-
ment field.
 (2) Primary and secondary reference fields of high-energy 
neutrons to allow for calibration of instruments to measure 
exposure.
 (3) Improved methods to reproducibly and consistently deter-
mine radiation quality.
 (4) Methods to accumulate exposures from therapeutic and 
imaging procedures.
 (5) Tools for risk visualization, analysis, communication, and 
documentation.
 (6) Algorithmic methods to support decision making in avoiding 
non-essential radiation risks.
Ideally, these will be implemented in ways that support the 
critical need for efficient, large-scale studies of the radiation late 
effects of proton therapy. When implemented, this will facilitate 
multidisciplinary research that integrates key aspects of radiation 
oncology (114), epidemiology (115, 116), physics (117), and 
survivorship (118, 119). In addition, this may be relevant to some 
radiobiologic research, such as abscopal (120) and other non-
targeted effects (e.g., radiation-induced bystander effect, genomic 
instability, and the radiation response of stem cells) (121) and 
modulation of radiation response (e.g., radiosensitizers and radio-
protectors) and novel combination therapies (122). The American 
Association of Physicists in Medicine pointed out potential 
dangers of using biological models for clinical radiotherapy and 
provided guidelines and methodology for quality assurance (123).
CONCLUSiON
In past decades, studies of medical exposures have increased 
knowledge of radiation risks. However, dose–response func-
tions have large uncertainties because many studies lacked the 
large sample sizes and high-quality radiation exposure data 
needed to more accurately estimate risk. Now, for the first 
time, it appears within reach, scientifically and technically, 
to prospectively calculate complete, whole-body exposures 
to virtually all major advanced technology radiotherapy 
patients. This will be possible because of widespread adop-
tion of the electronic medical record, improved understand-
ing of the physics of stray radiation exposures, advances in 
high-performance computing, and advances in algorithms to 
predict radiation exposures. When realized, the availability of 
exposure data for large populations will open new frontiers 
of research in radiation epidemiology, clinical oncology, and 
cancer survivorship.
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